CRP and hepatocellular carcinoma: Recent studies have suggested that CRP can serve as a surrogate biomarker for acute or chronic systemic inflammation, which may be poorly predicted by the MELD score in patients with ESLD, such as alcoholic hepatitis, hepatocellular carcinoma, tissue necrosis, and bacterial translocation.